{"organizations": [], "uuid": "e2aaf83ae6e6590908efa590174371875b61d8a2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180412.html", "section_title": "Archive News &amp; Video for Thursday, 12 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-advances-policy-to-make-develo/brief-fda-advances-policy-to-make-development-of-drugs-diagnostics-in-cancer-trials-more-efficient-idUSFWN1RP0OZ", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Advances Policy To Make Development Of Drugs & Diagnostics In Cancer Trials More Efficient", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-04-13T00:34:00.000+03:00", "replies_count": 0, "uuid": "e2aaf83ae6e6590908efa590174371875b61d8a2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-advances-policy-to-make-develo/brief-fda-advances-policy-to-make-development-of-drugs-diagnostics-in-cancer-trials-more-efficient-idUSFWN1RP0OZ", "ord_in_thread": 0, "title": "BRIEF-FDA Advances Policy To Make Development Of Drugs & Diagnostics In Cancer Trials More Efficient", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12 (Reuters) - U.S. Food and Drug Administration:\n* FDA ADVANCES POLICY TO MAKE CO-DEVELOPMENT OF DRUGS AND DIAGNOSTICS IN CANCER TRIALS MORE EFFICIENT\n* FDA SAYS IS STREAMLINING AGENCYâ€™S REVIEW OF CANCER DIAGNOSTICS THAT ARE DEVELOPED IN CONJUNCTION WITH DRUG TRIALS\n* ISSUING DRAFT GUIDANCE FOR CERTAIN ONCOLOGY TRIAL SPONSORS WITH OPTIONAL STREAMLINED SUBMISSION PROCESS REGARDING USE OF INVESTIGATIONAL IN VITRO DIAGNOSTIC\n* OPTIONAL SUBMISSION PROCESS DETERMINES WHETHER USE OF IVD IN CANCER TRIALS IS CONSIDERED SIGNIFICANT/NON-SIGNIFICANT RISK OR EXEMPT FROM FURTHER REVIEW Source text: ( bit.ly/2Hw1VYA )\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://bit.ly/2Hw1VYA", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-13T00:34:00.000+03:00", "crawled": "2018-04-13T17:55:55.010+03:00", "highlightTitle": ""}